Angiogenesis inhibitors.

被引：13
|
作者：
Tennant T.R. [1 ]
Rinker-Schaeffer C.W. [1 ]
Stadler W.M. [1 ]
机构：
[1] Section of Hematology/Oncology, University of Chicago, 5841 South Maryland, Chicago, 60637, IL
来源：
Current Oncology Reports | 2000年 / 2卷 / 1期
关键词：
Vascular Endothelial Growth Factor; Thalidomide; Angiogenesis Inhibitor; Clinical Trial Design; SU5416;
D O I：
10.1007/s11912-000-0005-0
中图分类号：
学科分类号：
摘要：
Angiogenesis inhibitors target the neovascular development that is hypothesized to underlie tumor growth. The inhibitors that are undergoing the clinical testing phase can be divided into five categories based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block angiogenesis activators; 4) drugs that inhibit endothelial cell integrins or survival signaling; and 5) drugs with a currently unknown mechanism of action. The properties of these drugs and some specific agents in each class are reviewed in this article. Because growth inhibition rather than tumor shrinkage is expected to be the clinical effect of angiogenesis inhibitors, some of the challenges and potential solutions for clinical trial design are also discussed.
引用
收藏
页码：11 / 16
页数：5
相关论文
共 50 条
  • [21] Benzothiepines are potent IBAT inhibitors.
    Reitz, D
    Huang, HC
    Carpenter, AJ
    Tollefson, MB
    Kolodziej, SA
    Li, JJ
    Wang, CC
    Garland, DJ
    Mahoney, MW
    Mischke, DA
    Chen, FP
    Reher, TR
    Reinhard, EJ
    Vernier,WF
    Huang, W
    Beaudry, JA
    Rapp, SR
    Smith, ME
    Schuh, JR
    Keller, BT
    Glenn, KC
    Tremont, SJ
    Lee, LF
    Banerjee, SS
    Both, SR
    Keller, K
    Miller, RE
    Wagner, GM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U316 - U316
  • [22] Design and synthesis of phosphatase inhibitors.
    Rosi, KS
    Kerns, JK
    Wilcox, CS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U62 - U62
  • [23] Evolving therapies: farnesyltransferase inhibitors.
    Purcell W.T.
    Donehower R.C.
    Current Oncology Reports, 2002, 4 (1) : 29 - 36
  • [24] Succinoyl benzazepinones as γ-secretase inhibitors.
    Olson, RE
    Wang, NH
    Frietze, WE
    Buckner, W
    Yang, MG
    Shi, JL
    Cochran, BM
    Zhao, KK
    Forsythe, T
    Richardson, L
    Decaire, M
    Wof, MA
    Roach, AH
    Burton, CR
    Meredith, JM
    Seiffert, DA
    Ren, S
    Golden, PL
    Richards, L
    Grossman, SA
    Zaczek, R
    Robertson, DW
    Wexler, RR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U965 - U965
  • [25] Hypersensitivity reactions to ACE inhibitors.
    LangauerMerrmer, S
    Bircher, AJ
    ALLERGOLOGIE, 1997, 20 (08) : 393 - 399
  • [26] Influenza susceptibility to neuraminidase inhibitors.
    Walker, Scot E.
    PHARMACOTHERAPY, 2013, 33 (10): : E297 - E297
  • [27] β-arylaminoketones as potent thrombin inhibitors.
    Bai, X
    Gu, X
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U130 - U130
  • [28] EVALUATING THE EFFECTIVENESS OF CORROSION INHIBITORS.
    Babei, Yu.I.
    Starchak, V.G.
    Klyachko, Yu.A.
    Berlin, A.A.
    Protection of Metals, 1976, 12 (03): : 305 - 306
  • [29] Development of historic deacetylase inhibitors.
    Richon, VM
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6272S - 6272S
  • [30] Virtual screening for kinase inhibitors.
    Lyne, PD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U365 - U365
12345